- Home
- KOD vs OPCH Comparison
KOD vs OPCH Comparison
Compare KOD & OPCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | OPCH |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KOD | OPCH |
|---|---|---|
| Price | $97.89 | $31.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 11 |
| Target Price | ★ $121.67 | $30.03 |
| AVG Volume (30 Days) | 1.3M | ★ 6.9M |
| Earning Date | 11-16-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.25 |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $4,998,202,000.00 |
| Revenue This Year | N/A | $1.91 |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | ★ N/A | $49.70 |
| Revenue Growth | N/A | ★ 16.17 |
| 52 Week Low | $15.83 | $18.01 |
| 52 Week High | $104.00 | $36.80 |
Technical Indicators
Market Signals| Indicator | KOD | OPCH |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 81.33 |
| Support Level | $81.11 | $28.70 |
| Resistance Level | $103.63 | $36.48 |
| Average True Range (ATR) | 6.38 | 0.13 |
| MACD | -0.88 | -0.17 |
| Stochastic Oscillator | 73.28 | 76.54 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.